AbbVie (NYSE:ABBV) announced Thursday that it will acquire Immunogen (IMGN) and its flagship cancer therapy, Elahere, in a deal worth $31.26 per share.
The transaction values ImmunoGen (NASDAQ:IMGN) at a total equity value of approximately $10.1 billion and is expected to close in the middle of 2024.
Elahere is considered a "first-in-class antibody-drug...
I was scanning stocks for chart patterns and came across Immunogen Inc. (IMGN) with a double-top already formed.
IMGN has been trading in a downward channel since February 2021 and shows no sign of stopping yet.
The price has reached a major support level of about 4.97, with only one major breach back in May. On three occasions it has dipped below slightly to...
